Breast cancer is known to be the leading cause of mortality in women worldwide. According to the presence of growth factor receptors on the surface of the cells it is divided into different subtypes [1] . HER2 is a growth factor receptor which belongs to the EGF-receptor family and is overexpressed in around 20% of all breast cancer cases [2] . HER2 positive breast cancer can nowadays be treated with neutralizing antibodies (Trastuzumab or Pertuzumab) or small compound inhibitors (Lapatinib), but the development of drug resistances remains a big problem in clinics [3] . Our aim is to understand the mechanism of trastuzumab treatment as well as the development of drug resistances. As individual cancer cells correspond differently towards therapy, we are interested in the action of trastuzumab on the single cell level [4] .
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HER2 was analyzed on the surface of cancer cells by labeling 1:1 with a biotinylated affibody followed by Trastuzumab treatment for different time points and incubation with streptavidin-conjugated quantum dot nanoparticles. Additionally, cells were co-stained with CD44 as a marker for stem cell subpopulation. Fluorescence microscopy was performed on the labeled cells followed by scanning transmission electron microscopy (STEM) analysis with nanometer resolution. Images were acquired from flat and ruffled surface regions of the cells. Exemplary images are shown in Figure 1 . The location of the quantum dots provides information about the spatial distribution of the HER2 receptors. Automatic label detection was used to analyze the distribution by pair correlation function analysis. HER2 was shown to be either present as single molecules or homo-dimers which is the cell growth signaling active state. Figure 1c shows the pair correlation function of QD-labeled HER2 in ruffled, flat and stem-like cells. The peak at 20-nm distance, indicating the presence of HER2 homo-dimers, was more pronounced in ruffled regions while in flat-and stem-like cancer cells, the occurrence of this inter-label distance stayed in the range of a random distribution. Incubation with the tested drug influenced the dimer peak in the pair correlation function. After 3 and 10 minutes of trastuzumab treatment, the presence of HER2 on the cell surface was already significantly reduced as well as the number of homo-dimers (Figure 1d ). The dimerization of the receptors was shown to vary in different parts of the cell. This suggests an influence of cell heterogeneity on the function of the receptors and hence on the drug response. The wet samples were coated with graphene to keep the cells in hydrated state during STEM imaging. Beam induced radiation damage dose series were performed on these samples (Figure 2a, b) . Therefore, the distance between two particles was measured for the respective electron doses applied to the sample. As seen in Figure 2c , no change was found in any of the samples up to a dose of (2.1±0.08)x10 3 e -/Å².
With our established protocols we are able to investigate HER2 distribution on the single cell level. It was 
